Allurion Expands into Asia with Launch of the Elipse� Gastric Balloon Weight Loss Program

Rapid organic growth in Europe, Middle East, and Latin America sets the stage for further global expansion

Company names John Liljequist as the Director of Sales for Asia Pacific

NATICK, Mass.–(BUSINESS WIRE)–Allurion Technologies, a pioneering leader in the development of innovative, scalable, and trusted weight loss experiences, today announced entry into Asia with the launch of the Elipse Program in Hong Kong, Malaysia, and Singapore. Building upon its success in Europe, Middle East, and Latin America, the company’s entry into Asia could impact the lives of over 1 billion people who are overweight or obese in a region that historically has had limited access to non-invasive weight loss treatments.¹

“With the launch of our weight loss program in Asia, our company enters its next phase of rapid expansion,” said Allurion co-founder and Chief Executive Officer, Shantanu Gaur, M.D. “Obesity has been on the rise in Asia for decades, but truly frictionless treatment options have been absent. We intend to change that.”

Allurion has already treated over 25,000 individuals in over 30 countries around the world with its 360-degree Allurion weight loss program. According to a study released by the Asian Development Bank Institute, over 40% of adults in Asia are overweight or obese, an increase of close to 20% in just the past 20 years.

“The arrival of the Elipse Balloon in Gleneagles Hospital Penang was a historical moment for all of us involved,” said Dr. Kirubakaran Malapan of Gleneagles Hospital Penang. “I am very confident that this will be an appealing treatment option in our fight against obesity.”

Allurion has also announced the addition of John Liljequist as the Director of Asia Pacific Sales. Mr. Liljequist has over 18 years of commercial medical device experience in the Asia Pacific region. Most recently he served as Senior Commercial Director at Establishment Labs and was responsible for driving sales, strategy and commercial activities across Japan, Korea, Hong Kong, Australia, and China. Prior to Establishment Labs, Mr. Liljequist managed the breast implant franchise at Allergan and was the integration lead for Coolsculpting^® across APAC, India, Middle East, and Africa.

“I am delighted to have John join the Allurion commercial team,” said Benoit Chardon, Allurion Executive Vice President of Global Commercial. “He is a joining at a time of substantial growth and will have an opportunity to deploy his talent, experience, and passion in one of the fastest growing weight loss markets in the world.”

About Allurion Technologies

Allurion Technologies is dedicated to helping people realize their full potential with innovative, scalable and trusted experiences. The company’s flagship product, the Allurion Program, is a 360-degree weight loss experience featuring the Elipse Balloon, the world’s first and only swallowable, procedureless gastric balloon for weight loss. Learn more about the Elipse Balloon and Allurion online at www.allurion.com, on Facebook at www.fb.com/allurion or on Twitter @alluriontech. The Elipse Balloon is not approved by the FDA and is an investigational device in the United States.

¹https://www.adb.org/sites/default/files/publication/320411/adbi-wp743.pdf

Contacts

Whitney Cypes

(408) 547-7531